Altogether, our study showed the tumor inhibition effect of DHX9-HDAC5-BECN1 axis in ER+ and TNBC cell lines, implying the therapeutic potential of DHX9 or HDAC5 inhibitors in at least HR+ or TNBC subtypes. Here, HDAC5 is linked to neoplasm.